雷洛昔芬的影响在绝经后妇女患乳腺癌的风险:更多的随机试验的结果。雷洛昔芬的多个结果评估。
文章的细节
-
引用
复制到剪贴板 -
卡明斯SR,埃克特年代,克鲁格KA, Grady D, Powles TJ, Cauley是的,诺顿L, Nickelsen T, Bjarnason NH,明日M,利普曼我,黑D, Glusman我,哥,乔丹VC
雷洛昔芬的影响在绝经后妇女患乳腺癌的风险:更多的随机试验的结果。雷洛昔芬的多个结果评估。
《美国医学协会杂志》上。1999年6月16日,281 (23):2189 - 97。
- PubMed ID
-
10376571 (在PubMed]
- 文摘
-
背景:盐酸雷洛昔芬是一个选择性雌激素受体调节剂,对乳腺癌和子宫内膜组织和抗雌激素的影响雌激素对骨的影响,脂质代谢和血液凝结。目的:确定服用雷洛昔芬的女性是否具有浸润性乳腺癌的风险较低。设计和设置:雷洛昔芬的多个结果评价(更多),一个多中心、随机、双盲试验中,服用雷洛昔芬的女性或安慰剂进行了中位数的40个月(SD, 3年),从1994年到1998年,在180个临床中心由社区设置在25个国家和医疗实践,主要集中在美国和欧洲。参与者:总共有7705名绝经后妇女,小于81(平均年龄,66.5)年,骨质疏松症,定义的存在椎脊柱骨折、股骨颈或t指数至少2.5 SDs低于年轻健康女性的意思。几乎所有的参与者(96%)是白人。女性乳腺癌的历史或服用雌激素被排除在外。干预:雷洛昔芬,60毫克,每日2片;雷洛昔芬,60毫克,每天1片,1安慰剂的平板电脑;或2安慰剂药片。主要结果测量:乳腺癌的新病例,经组织病理学证实。 Transvaginal ultrasonography was used to assess the endometrial effects of raloxifene in 1781 women. Deep vein thrombosis or pulmonary embolism were determined by chart review. RESULTS: Thirteen cases of breast cancer were confirmed among the 5129 women assigned to raloxifene vs 27 among the 2576 women assigned to placebo (relative risk [RR], 0.24; 95% confidence interval [CI], 0.13-0.44; P<.001). To prevent 1 case of breast cancer, 126 women would need to be treated. Raloxifene decreased the risk of estrogen receptor-positive breast cancer by 90% (RR, 0.10; 95% CI, 0.04-0.24), but not estrogen receptor-negative invasive breast cancer (RR, 0.88; 95% CI, 0.26-3.0). Raloxifene increased the risk of venous thromboembolic disease (RR, 3.1; 95% CI, 1.5-6.2), but did not increase the risk of endometrial cancer (RR, 0.8; 95% CI, 0.2-2.7). CONCLUSION: Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene.